Discovery of a High Affinity and Selective Pyridine Analog as a Potential Positron Emission Tomography Imaging Agent for Cannabinoid Type 2 Receptor
摘要:
As part of our efforts to develop CB2 PET imaging agents, we investigated 2,5,6-substituted pyridines as a novel class of potential CB2 PET ligands. A total of 21 novel compounds were designed, synthesized, and evaluated for their potency and binding properties toward human and rodent CB1 and CB2. The most promising ligand 6a was radiolabeled with carbon-11 to yield 16 ([C-11]RSR-056). Specific binding of 16 to CB2-positive spleen tissue of rats and mice was demonstrated by in vitro autogadiography and verified in vivo in PET and biodistribution experiments. Furthermore, 16 was evaluated in a lipopolysaccharid (LPS) induced murine model of neuroinflammation. Brain radioactivity was strikingly higher in the LPS-treated mice than the control mice. Compound 16 is a promising radiotracer for imaging CB2 in rodents. It might serve as a tool for the investigation of CB2 receptor expression levels in healthy tissues and different neuroinflammatory disorders in humans.
[EN] PYRIDIN- 2 -AMIDES USEFUL AS CB2 AGONISTS<br/>[FR] PYRIDIN-2-AMIDES UTILES COMME AGONISTES DE CB2
申请人:HOFFMANN LA ROCHE
公开号:WO2012168350A1
公开(公告)日:2012-12-13
The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
[EN] PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS<br/>[FR] PYRIDINE-2-AMIDES UTILES COMME AGONISTES DE CB2
申请人:HOFFMANN LA ROCHE
公开号:WO2014086805A1
公开(公告)日:2014-06-12
The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) is a CB2 agonist and can be used as an active ingredient in a medicament.
The invention relates to a compound of formula (I)
wherein R
1
to R
4
are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament. In particular, the compound may be used as a preferential agonist of Cannabinoid Receptor 2.
[EN] NOVEL PYRAZINE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS DE PYRAZINE
申请人:HOFFMANN LA ROCHE
公开号:WO2013060751A1
公开(公告)日:2013-05-02
The invention relates to a compound of formula (I), wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
[EN] 5,6-DISUBSTITUTED PYRIDINE-2-CARBOXAMIDES AS CANNABINOID RECEPTOR AGONISTS<br/>[FR] PYRIDINE-2-CARBOXAMIDES BISUBSTITUÉS EN 5,6 SERVANT D'AGONISTES DU RÉCEPTEUR CANNABINOÏDE
申请人:HOFFMANN LA ROCHE
公开号:WO2015150438A1
公开(公告)日:2015-10-08
The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) are agonists of the Cannabinoid Receptor 2 and are therefore useful in the treatment of various diseases such as pain, atherosclerosis, inflammation etc.